XFOR insider transaction filings
X4 Pharmaceuticals, Inc — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-13. Screen XFOR transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 4 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 3 legs across 3 filings by 3 insiders — 80,555 shares, $356,486 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 1.
- Largest priced transaction: sale of 47,436 shares @ $4.44 ($210,829) by Craig Adam R, filed 2026-08-13.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Craig Adam R — Executive Chairman, Director | 1 | — | 1 leg · 47,436 sh · $210,829 | — |
| Volpone John — President | 1 | — | 1 leg · 24,576 sh · $109,228 | — |
| KIRSKE DAVID — Chief Financial Officer | 1 | — | 1 leg · 8,543 sh · $36,428 | — |
| Gold Kelly — Director | 1 | — | — | 1 |
Recent Form 4 filings — X4 Pharmaceuticals, Inc
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-13 | 4 | Volpone John — President | Sale (S): 24,576 @ $4.44 | EDGAR |
| 2026-08-13 | 4 | Craig Adam R — Executive Chairman, Director | Sale (S): 47,436 @ $4.44 | EDGAR |
| 2026-07-01 | 4 | Gold Kelly — Director | Grant/award (A): 110,000 (derivative) @ $0 | EDGAR |
| 2026-07-01 | 4 | KIRSKE DAVID — Chief Financial Officer | Sale (S): 8,543 @ $4.26 | EDGAR |
| 2026-05-13 | 4 | KIRSKE DAVID — Chief Financial Officer | Sale (S): 16,961 @ $4.29 | EDGAR |
| 2026-01-07 | 4 | Bridger Gary — Director | Grant/award (A): 110,000 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | de Craecker Francoise — Director | Grant/award (A): 110,000 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | Stewart Murray — Director | Grant/award (A): 110,000 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | WYZGA MICHAEL S — Director | Grant/award (A): 110,000 (derivative) @ $0 | EDGAR |
| 2025-10-31 | 4 | Volpone John — President | Grant/award (A): 2,329,154 (derivative) @ $0 | EDGAR |
| 2025-10-31 | 4 | Craig Adam R — Executive Chairman, Director | Grant/award (A): 2,329,154 (derivative) @ $0 | EDGAR |
| 2025-10-31 | 4 | KIRSKE DAVID — Chief Financial Officer | Grant/award (A): 1,552,769 (derivative) @ $0 | EDGAR |
| 2025-10-27 | 4 | Craig Adam R — Executive Chairman, Director | Purchase (P): 86,206 @ $2.90 | EDGAR |
| 2025-08-14 | 4 | Volpone John — President | Grant/award (A): 289,881 @ $0 · Grant/award (A): 1,609,873 (derivative) @ $0 · Grant/award (A): 529,201 (derivative) @ $0 | EDGAR |
| 2025-08-14 | 4 | Craig Adam R — Executive Chairman, Director | Grant/award (A): 289,881 @ $0 · Grant/award (A): 1,609,873 (derivative) @ $0 · Grant/award (A): 529,201 (derivative) @ $0 | EDGAR |
| 2025-08-14 | 4 | KIRSKE DAVID — Chief Financial Officer | Grant/award (A): 193,254 @ $0 · Grant/award (A): 1,073,249 (derivative) @ $0 · Grant/award (A): 352,800 (derivative) @ $0 | EDGAR |
| 2025-07-03 | 4 | Thoren Natasha Fay — Chief Legal Officer | Grant/award (A): 3,333 @ $0 | EDGAR |
| 2025-06-10 | 4 | Stewart Murray — Director | Grant/award (A): 1,500 @ $0 | EDGAR |
| 2025-06-10 | 4 | de Craecker Francoise — Director | Grant/award (A): 1,500 @ $0 | EDGAR |
| 2025-06-10 | 4 | Bridger Gary — Director | Grant/award (A): 1,500 @ $0 | EDGAR |
| 2025-06-10 | 4 | Woods Keith — Director | Grant/award (A): 1,500 @ $0 | EDGAR |
| 2025-06-10 | 4 | MCGIRR DAVID W J — Director | Grant/award (A): 1,500 @ $0 | EDGAR |
| 2025-06-10 | 4 | WYZGA MICHAEL S — Director | Grant/award (A): 1,500 @ $0 | EDGAR |
| 2025-06-03 | 4/A | Baldry Mark — Chief Commercial Officer | Grant/award (A): 1,032 @ $2.48 | EDGAR |
| 2025-05-20 | 4 | Baldry Mark — Chief Commercial Officer | Purchase (P): 1,032 @ $2.48 | EDGAR |
| 2025-02-14 | 4 | Arbet-Engels Christophe — Chief Medical Officer | Grant/award (A): 850,000 @ $0 | EDGAR |
| 2025-02-14 | 4 | Mostafa Adam S. — Chief Financial Officer | Grant/award (A): 850,000 @ $0 | EDGAR |
| 2025-02-14 | 4 | Ragan Paula — President and CEO, Director | Grant/award (A): 2,250,000 @ $0 | EDGAR |
| 2025-02-14 | 4 | Baldry Mark — Chief Commercial Officer | Purchase (P): 21,646 @ $0.68 · Purchase (P): 13,404 @ $0.34 · Grant/award (A): 600,000 @ $0 | EDGAR |
| 2025-02-14 | 4 | DiBiase Mary — Chief Operating Officer | Grant/award (A): 650,000 @ $0 | EDGAR |
| 2025-01-27 | 4 | Ragan Paula — President and CEO, Director | Grant/award (A): 169,940 @ $0 · Sale (S): 76,473 @ $0.45 | EDGAR |
| 2025-01-27 | 4 | Mostafa Adam S. — Chief Financial Officer | Grant/award (A): 74,773 @ $0 · Sale (S): 74,773 @ $0.45 | EDGAR |
| 2025-01-27 | 4 | Baldry Mark — Chief Commercial Officer | Grant/award (A): 74,773 @ $0 · Sale (S): 29,159 @ $0.45 | EDGAR |
| 2025-01-27 | 4 | DiBiase Mary — Chief Operating Officer | Grant/award (A): 61,178 @ $0 · Sale (S): 22,258 @ $0.45 | EDGAR |
| 2025-01-27 | 4 | Arbet-Engels Christophe — Chief Medical Officer | Grant/award (A): 25,831 @ $0 · Sale (S): 11,624 @ $0.45 | EDGAR |
| 2024-11-19 | 4 | Ragan Paula — President and CEO, Director | Sale (S): 31,897 @ $0.39 | EDGAR |
| 2024-10-16 | 4 | Ragan Paula — President and CEO, Director | Sale (S): 31,897 @ $0.56 | EDGAR |
| 2024-10-08 | 4 | Mostafa Adam S. — Chief Financial Officer | Grant/award (A): 230,645 @ $0 · Sale (S): 230,645 @ $0.55 | EDGAR |
| 2024-10-08 | 4 | Baldry Mark — Chief Commercial Officer | Grant/award (A): 34,946 @ $0 · Sale (S): 11,127 @ $0.58 | EDGAR |
| 2024-10-08 | 4 | Ragan Paula — President and CEO, Director | Grant/award (A): 532,081 @ $0 · Sale (S): 239,436 @ $0.55 | EDGAR |
| 2024-10-08 | 4 | DiBiase Mary — Chief Operating Officer | Grant/award (A): 230,645 @ $0 · Sale (S): 67,695 @ $0.57 | EDGAR |
| 2024-10-08 | 4 | Taveras Arthur — Chief Scientific Officer | Grant/award (A): 230,645 @ $0 · Sale (S): 76,920 @ $0.56 | EDGAR |
| 2024-09-11 | 4 | DiBiase Mary — Chief Operating Officer | Sale (S): 2,642 @ $0.66 | EDGAR |
| 2024-06-11 | 4 | Aliski William — Director | Grant/award (A): 45,000 @ $0 | EDGAR |
| 2024-06-11 | 4 | Stewart Murray — Director | Grant/award (A): 45,000 @ $0 | EDGAR |
| 2024-06-11 | 4 | Bridger Gary — Director | Grant/award (A): 45,000 @ $0 | EDGAR |
| 2024-06-11 | 4 | Woods Keith — Director | Grant/award (A): 45,000 @ $0 | EDGAR |
| 2024-06-11 | 4 | Lawton Alison Frances — Director | Grant/award (A): 45,000 @ $0 | EDGAR |
| 2024-06-11 | 4 | MCGIRR DAVID W J — Director | Grant/award (A): 45,000 @ $0 | EDGAR |
| 2024-06-11 | 4 | WYZGA MICHAEL S — Director | Grant/award (A): 45,000 @ $0 | EDGAR |
Recent 8-K events — X4 Pharmaceuticals, Inc
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-09 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-08 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-01 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-13 | 8-K/A | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-12 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2025-11-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-10-27 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-09-17 | 8-K | ? 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-08-25 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2025-08-13 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=XFOR returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →